NCT06090331 2025-07-08
89Zr-DFO-girentuximab Expanded Access Program (EAP)
Telix Pharmaceuticals (Innovations) Pty Limited
Available
Clinical Trials
6 trialsNCT04100694 2025-05-20
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus B.V.
Approved for marketing
NCT03874455 2024-03-22
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Ipsen
No longer available
NCT03554434 2020-03-02
An Expanded Access Program for AM0010 (Pegilodecakin)
Eli Lilly and Company
No longer available
NCT01473043 2014-05-30
Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment
Pfizer
No longer available
NCT00655252 2011-08-19
Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy
Novartis
No longer available